Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and aprepitant

quinazolines has been researched along with aprepitant in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hussar, DA1
Santini, D; Tonini, G; Vincenzi, B1
Levêque, D1
Blanchet, B; Goldwasser, F; Mir, O1
Buhren, BA; Gerber, PA; Homey, B1
Chmielinska, JJ; Kramer, JH; Mak, IT; Spurney, CF; Weglicki, WB1

Other Studies

6 other study(ies) available for quinazolines and aprepitant

ArticleYear
New drugs 04. Part III.
    Nursing, 2004, Volume: 34, Issue:9

    Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides

2004
Aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2010, Jul-22, Volume: 363, Issue:4

    Topics: Adult; Aged; Aprepitant; Erlotinib Hydrochloride; Female; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Kinase Inhibitors; Pruritus; Quinazolines

2010
Aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2010, 10-21, Volume: 363, Issue:17

    Topics: Antineoplastic Agents; Aprepitant; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines

2010
More on aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2011, 02-03, Volume: 364, Issue:5

    Topics: Adenocarcinoma; Aprepitant; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines

2011
More on aprepitant for erlotinib-induced pruritus.
    The New England journal of medicine, 2011, 02-03, Volume: 364, Issue:5

    Topics: Antiemetics; Aprepitant; Erlotinib Hydrochloride; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Off-Label Use; Protein Kinase Inhibitors; Pruritus; Quinazolines; Substance P

2011
EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.
    Journal of cardiovascular pharmacology, 2015, Volume: 65, Issue:1

    Topics: Animals; Aprepitant; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Magnesium; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-1; Substance P; Ventricular Function, Left

2015